Influence of Exceptional Patient Characteristics on Everolimus Exposure
Status:
Completed
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
A study to determine whether everolimus pharmacokinetics in elderly and obese patients is
different compared to control patients.
Furthermore the investigators will investigate the relation between metabolic response
assessed with [18F] Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and everolimus
exposure and clinical benefit.
The investigators will explore whether dose escalation in patients who are hypothetically
underexposed will result in an increase in metabolic response.